Polymorphisms in the Promoter Region of the Gene As a Predictive Factor for the First-line CTD Therapy in Multiple Myeloma Patients

Overview

Journal Oncotarget

Specialty Oncology

Date 2018 May 31

PMID 29844872

Citations 4

Authors

Aneta Szudy-Szczyrek

Radoslaw Mlak

Michal Szczyrek

Sylwia Chocholska

Jacek Sompor

Adam Nogalski

Teresa Malecka-Massalska

Marek Hus

Affiliations

Soon will be listed here.

Abstract

Cereblon is a primary molecular target for immunomodulatory drugs. The aim of this study was to evaluate the influence of selected clinical and molecular factors including single nucleotide polymorphisms (SNPs) in gene on the efficacy of first line CTD (cyclophosphamide, thalidomide, dexamethasone) chemotherapy in patients with multiple myeloma. Study group consisted of 68 patients. Analysis of CRBN gene SNPs (rs6768972, rs1672753) was performed using Real-Time PCR genotyping technique. Median progression free survival (PFS) was 15 months and overall survival (OS) 79 months. Factors associated with significantly shorter OS included ISS 3, kidney disease, weight loss, anemia, thrombocytopenia, hypoalbuminemia, elevated β2-microglobuline and CRP. The presence of t(4;14) was associated with significantly shorter PFS and OS. Both examined SNPs proved to be statistically significant, independent predictive factors of efficacy of the CTD chemotherapy. The presence of AA genotype (rs6768972) correlated with longer median PFS (18 vs 9 months; HR=0.49,95% CI: 0.26-0.91, p=0.0062). Conversely, in the carriers of CC genotype (rs1672753) significantly shorter median PFS was observed (4 vs 16 months; HR=3.93, 95% CI: 0.26-59.64, p=0.0321). In conclusion, SNPs of the gene may be useful in qualifying patients for treatment with regimens containing thalidomide.

Citing Articles

RXR Agonists Enhance Lenalidomide Anti-Myeloma Activity and T Cell Functions while Retaining Glucose-Lowering Effect.

Wu J, Wang X, Zhang M, Mathews P, Kang Y Cells. 2023; 12(15).

PMID: 37566072 PMC: 10417536. DOI: 10.3390/cells12151993.

Evaluation of the influence of genetic variants in Cereblon gene on the response to the treatment of erythema nodosum leprosum with thalidomide.

Costa P, Maciel-Fiuza M, Kowalski T, Fraga L, Feira M, Aranha Camargo L Mem Inst Oswaldo Cruz. 2022; 117:e220039.

PMID: 36383784 PMC: 9668341. DOI: 10.1590/0074-02760220039.

CRL4-Cereblon complex in Thalidomide Embryopathy: a translational investigation.

Kowalski T, Gomes J, Garcia G, Fraga L, Paixao-Cortes V, Recamonde-Mendoza M Sci Rep. 2020; 10(1):851.

PMID: 31964914 PMC: 6972723. DOI: 10.1038/s41598-020-57512-x.

Cereblon gene variants and clinical outcome in multiple myeloma patients treated with lenalidomide.

Huang P, Beedie S, Chau C, Venzon D, Gere S, Kazandjian D Sci Rep. 2019; 9(1):14884.

PMID: 31619706 PMC: 6795854. DOI: 10.1038/s41598-019-51446-9.

References

Fionda C, Abruzzese M, Zingoni A, Cecere F, Vulpis E, Peruzzi G . The IMiDs targets IKZF-1/3 and IRF4 as novel negative regulators of NK cell-activating ligands expression in multiple myeloma. Oncotarget. 2015; 6(27):23609-30. PMC: 4695140. DOI: 10.18632/oncotarget.4603. View

Greipp P, San Miguel J, Durie B, Crowley J, Barlogie B, Blade J . International staging system for multiple myeloma. J Clin Oncol. 2005; 23(15):3412-20. DOI: 10.1200/JCO.2005.04.242. View

Duffy M, Crown J . A personalized approach to cancer treatment: how biomarkers can help. Clin Chem. 2008; 54(11):1770-9. DOI: 10.1373/clinchem.2008.110056. View

Robert J, Le Morvan V, Smith D, Pourquier P, Bonnet J . Predicting drug response and toxicity based on gene polymorphisms. Crit Rev Oncol Hematol. 2005; 54(3):171-96. DOI: 10.1016/j.critrevonc.2005.01.005. View

Dmoszynska A, Walter-Croneck A, Hus I, Grzasko N, Manko J, Jedrzejczak W . The efficacy and safety of the low-thalidomide dose CTD (cyclophosphamide, thalidomide, dexamethasone) regimen in patients with multiple myeloma--a report by the Polish Myeloma Study Group. Leuk Res. 2010; 34(10):1330-5. DOI: 10.1016/j.leukres.2010.05.003. View

Schuster S, Kortuem K, Zhu Y, Braggio E, Shi C, Bruins L . The clinical significance of cereblon expression in multiple myeloma. Leuk Res. 2013; 38(1):23-8. PMC: 3905958. DOI: 10.1016/j.leukres.2013.08.015. View

Barlogie B, Desikan R, Eddlemon P, Spencer T, Zeldis J, Munshi N . Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood. 2001; 98(2):492-4. DOI: 10.1182/blood.v98.2.492. View

Offidani M, Corvatta L, Polloni C, Piersantelli M, Galieni P, Visani G . Serum C-reactive protein at diagnosis and response to therapy is the most powerful factor predicting outcome of multiple myeloma treated with thalidomide/ anthracycline-based therapy. Clin Lymphoma Myeloma. 2008; 8(5):294-9. DOI: 10.3816/CLM.2008.n.041. View

Chang W, Kang E, Lee S, Kim S, Kim D, Kim S . Thalidomide, cyclophosphamide and dexamethasone induction therapy: feasibility for myeloma patients destined for autologous stem cell transplantation. Acta Haematol. 2014; 132(2):226-32. DOI: 10.1159/000357659. View

10.

Siegel R, Miller K, Jemal A . Cancer statistics, 2016. CA Cancer J Clin. 2016; 66(1):7-30. DOI: 10.3322/caac.21332. View

11.

Unger F, Witte I, David K . Prediction of individual response to anticancer therapy: historical and future perspectives. Cell Mol Life Sci. 2014; 72(4):729-57. PMC: 4309902. DOI: 10.1007/s00018-014-1772-3. View

12.

Harousseau J, Attal M, Avet-Loiseau H . The role of complete response in multiple myeloma. Blood. 2009; 114(15):3139-46. DOI: 10.1182/blood-2009-03-201053. View

13.

Sze D, Brown R, Yang S, Ho P, Gibson J, Joshua D . The use of thalidomide in myeloma therapy as an effective anticancer drug. Curr Cancer Drug Targets. 2006; 6(4):325-31. DOI: 10.2174/156800906777441762. View

14.

Kastritis E, Zervas K, Symeonidis A, Terpos E, Delimbassi S, Anagnostopoulos N . Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG). Leukemia. 2009; 23(6):1152-7. DOI: 10.1038/leu.2008.402. View

15.

Morgan G, Davies F, Gregory W, Bell S, Szubert A, Navarro Coy N . Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results. Haematologica. 2011; 97(3):442-50. PMC: 3291601. DOI: 10.3324/haematol.2011.043372. View

16.

Morgan G, Davies F, Gregory W, Russell N, Bell S, Szubert A . Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation. Blood. 2011; 118(5):1231-8. PMC: 3152492. DOI: 10.1182/blood-2011-02-338665. View

17.

Huang S, Lin C, Lin H, Yao M, Tang J, Wu S . Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma. Ann Hematol. 2014; 93(8):1371-80. PMC: 4082140. DOI: 10.1007/s00277-014-2063-7. View

18.

Kumar S, Rajkumar S, Dispenzieri A, Lacy M, Hayman S, Buadi F . Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2007; 111(5):2516-20. PMC: 2254544. DOI: 10.1182/blood-2007-10-116129. View

19.

Butrym A, Lacina P, Rybka J, Chaszczewska-Markowska M, Mazur G, Bogunia-Kubik K . Cereblon and IRF4 Variants Affect Risk and Response to Treatment in Multiple Myeloma. Arch Immunol Ther Exp (Warsz). 2017; 64(Suppl 1):151-156. PMC: 5334380. DOI: 10.1007/s00005-016-0442-6. View

20.

Boyd K, Ross F, Chiecchio L, Dagrada G, Konn Z, Tapper W . Gender disparities in the tumor genetics and clinical outcome of multiple myeloma. Cancer Epidemiol Biomarkers Prev. 2011; 20(8):1703-7. PMC: 4545514. DOI: 10.1158/1055-9965.EPI-11-0157. View